Inflation Uptick Sparks Broad Sell-Off 📉

Stocks plummeted after March's CPI report showed inflation continues to accelerate, and investors fear the Fed may be forced to further delay rate its rate cut plans.                                                                                                                                                                                                                                                                                                                                                                                                                 April 10, 2024 | [Read Online]( Good Afternoon! Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today. Markets 📈 Stocks sold off after a hotter-than-expected March CPI report dashed hopes for an imminent rate cut. Small-caps underperformed, while the Dow posted the steepest loss among large-cap indexes. - DJIA [-1.0%] - S&P 500 [-0.9%] - Nasdaq [-0.8%] - Russell 2K [-2.6%] [Titanium Shortage Threatens Industry Titan]( (Ad) A titan of the aerospace industry announced it would no longer purchase titanium from Russia, a key supplier. With a global shortage of the lightweight "wonder metal" already in play, aerospace-grade titanium has become particularly scarce. Will investors find new opportunity amid this titanium crisis? [Get the ticker & a full briefing HERE »]( » Want an Ad-Free Experience + Top Growth Stock Picks? [Upgrade Now!]( Market-Moving News 🔎 🤦🏻‍♂️ The Fed is in a Tough Spot After March CPI Report The consumer-price index (CPI) for March, showing a year-over-year increase of 3.5%, has become a focal point for the Federal Reserve, especially after the willingness to overlook higher-than-expected inflation readings in January and February. This recent surge underscores the heightened scrutiny on inflation trends and the Fed's response strategy. Powell's Stance ⚖️ Fed Chair Jerome Powell has been navigating through the complexities of recent inflation data, emphasizing the need for a balanced approach to potential interest rate cuts. Despite previous periods of improvement, the latest CPI data may challenge the Fed's threshold for action, especially with Powell highlighting the significance of forthcoming decisions in a "highly consequential" economic context. Market Skepticism 💡 The market's reaction to the March CPI report reflects growing skepticism towards the Fed's capacity to lower rates in the near term. Initially, expectations leaned towards multiple rate cuts throughout the year, but the outlook has shifted dramatically, with predictions now suggesting a more cautious, limited approach, potentially impacting the broader economic landscape and future policy directions. Interest Rate Outlook 🏦 The resilience of economic activity, combined with the latest inflation trends, has led to a recalibration of expectations for the Fed's interest rate policy. Traders now anticipate that rates could remain elevated through the end of 2025, a scenario that could have far-reaching implications for both the economy and monetary policy moving forward. "Bumps" Ahead 🚧 As the Fed evaluates its policy options in the face of recent inflation data, the broader economic implications loom large. The March CPI report, alongside Powell's cautious yet open stance on rate adjustments, sets the stage for a critical period in the Fed's efforts to manage inflation while supporting ongoing economic growth and stability. Top Winners and Losers 🔥 Adial Pharma [ADIL] $2.33 (+106.1%) published new clinical research showing its AD04 drug produced favorable results, a strong safety profile, and high patient compliance. Rent the Runway [RENT] $7.40 (+36.2%) rallied in anticipation of its Q4 results, which were published after the closing bell. RENT is up another 40.9% in the aftermarket. Marin Software [MRIN] $0.6497 (+126.3%) announced enhancements to its Microsoft Advertising integration. Processa Pharma [PCSA] $1.84 (36.7%) slid after Refinitiv/Verus downgraded the stock from “HOLD” to “SELL” on Monday. Aptevo [APVO] $2.40 (26.3%) announced advancements in some of its clinical and preclinical programs that weren’t received well by the market. Palisade Bio [PALI] $4.07 (24.9%) presented a development overview for PAL-2108 at the Crohn’s & colitis industry conference in Cambridge, MA. That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback from our members! Thanks for reading. I'll see you at the next open! Best Regards, — Adam G. Elite Trade Club Text ELITESTOCKS to 47121 or [click here]( to get our alerts on your mobile device, and never miss another fast-moving stock! P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP. [Sign Up for Mobile Alerts Now]( [Privacy Policy]( | [Advertiser Disclosure]( [tw]( [ig]( [yt]( [tk]( *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails. [Privacy Policy]( | [Terms of Service]( Update your email preferences or unsubscribe [here]( © 2024 Elite Trade Media LLC 1969 Alafaya Tr., Suite #247 Orlando, Florida 32828, United States of America [[beehiiv logo]Powered by beehiiv](